Wampole Chelsea, McKenna Ariel, Riker Richard R, May Teresa L, Seder David B, Abram Dawn, Fraser Gilles L, Gagnon David J
Department of Pharmacy, Maine Medical Center, Portland, ME.
Department of Medicine, Maine Medical Center, Portland, ME.
Crit Care Explor. 2022 Jul 26;4(7):e0735. doi: 10.1097/CCE.0000000000000735. eCollection 2022 Jul.
The association between opioid therapy during critical illness and persistent opioid use after discharge is understudied relative to ICU opioid exposure and modifiable risk factors. Our objectives were to compare persistent opioid use after discharge among patients with and without chronic opioid use prior to admission (OPTA) and identify risk factors associated with persistent use.
Retrospective cohort study.
Medical, trauma/surgical, or neurologic ICU at an academic hospital.
Adult patients surviving hospital admission.
Opioid use during the ICU and post-ICU stays.
The primary outcome was persistent opioid use accounting for greater than 70% of days 4-6 months after discharge. Among 2,975 included patients, 257 (8.6%) were classified as OPTA, and 305 (10.2%) persistently filled opioid prescriptions, including 186/257 (72%) OPTA and 119/2,718 (4.4%) with no chronic opioid fills prior to admission. Among all patients, OPTA was strongly associated with persistent opioid use (odds ratio, 57.2 [95% CI, 41.4-80.0]). Multivariable logistic regression revealed that male sex, surgical procedure, and ICU opioid-free days were associated with reduced persistent opioid use for OPTA patients. Age and ICU opioid-free days were associated with reduced persistent opioid use for non-OPTA patients. Total ICU opioid dose and dose per day of ICU exposure were not associated with persistent use for either group.
In this mixed cohort of ICU patients, 10.2% persistently filled opioid prescriptions 4-6 months after discharge. Although ICU opioid doses were not associated with persistent use, duration of ICU opioid administration is a modifiable risk factor that may reduce persistent opioid use after critical illness.
与重症监护病房(ICU)阿片类药物暴露及可改变的风险因素相比,危重症期间阿片类药物治疗与出院后持续使用阿片类药物之间的关联研究较少。我们的目的是比较入院前有和没有长期使用阿片类药物(OPTA)的患者出院后持续使用阿片类药物的情况,并确定与持续使用相关的风险因素。
回顾性队列研究。
一所学术医院的内科、创伤/外科或神经科ICU。
入院存活的成年患者。
ICU期间及ICU后住院期间使用阿片类药物。
主要结局是出院后4至6个月持续使用阿片类药物,占比超过70%。在纳入的2975例患者中,257例(8.6%)被归类为OPTA,305例(10.2%)持续开具阿片类药物处方,其中包括186/257(72%)例OPTA患者和119/2718(4.4%)例入院前无长期阿片类药物处方的患者。在所有患者中,OPTA与持续使用阿片类药物密切相关(比值比,57.2 [95% CI,41.4 - 80.0])。多变量逻辑回归显示,男性、手术操作和ICU无阿片类药物使用天数与OPTA患者持续使用阿片类药物减少有关。年龄和ICU无阿片类药物使用天数与非OPTA患者持续使用阿片类药物减少有关。两组患者的ICU阿片类药物总剂量和ICU暴露期间每日剂量均与持续使用无关。
在这个混合的ICU患者队列中,10.2%的患者在出院后4至6个月持续开具阿片类药物处方。虽然ICU阿片类药物剂量与持续使用无关,但ICU阿片类药物给药持续时间是一个可改变的风险因素,可能会减少危重症后持续使用阿片类药物的情况。